Tags

Type your tag names separated by a space and hit enter

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
J Antimicrob Chemother. 2014 Oct; 69(10):2713-22.JA

Abstract

OBJECTIVES

To evaluate the in vitro activity of ceftolozane/tazobactam and comparator agents tested against contemporary Gram-negative bacteria. Ceftolozane/tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor.

METHODS

A total of 10 532 Gram-negative organisms (2191 Pseudomonas aeruginosa and 8341 Enterobacteriaceae) were consecutively collected from 31 medical centres located in 13 European countries plus Turkey and Israel. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A9 document and the results interpreted according to EUCAST as well as CLSI breakpoint criteria. Selected ceftazidime- and/or meropenem-resistant P. aeruginosa isolates were screened for the presence of β-lactamase genes by PCR.

RESULTS

P. aeruginosa exhibited high rates of multidrug-resistant (31.9%) and extensively drug-resistant (24.6%) isolates and 11.6% of isolates were susceptible only to colistin. When tested against P. aeruginosa, ceftolozane/tazobactam (MIC(50), 1 mg/L) was generally 4-fold more active than ceftazidime (MIC(50), 4 mg/L) and inhibited >90% of isolates with an MIC of ≤8 mg/L in nine countries. In contrast, the highest susceptibility rates observed for ceftazidime and meropenem, respectively, were 86.0%/86.0% (UK) and 85.2%/86.1% (Ireland) (67.2%/67.1% overall). Ceftolozane/tazobactam (MIC(50/90), 0.25/2 mg/L; 93.7% and 95.2% inhibited at ≤4 and ≤8 mg/L, respectively), meropenem [MIC(50/90), ≤0.06/≤0.06 mg/L; 98.0% susceptible (EUCAST)] and tigecycline [MIC(50/90), 0.12/1 mg/L; 94.1% susceptible (EUCAST)] were the most active compounds tested against Enterobacteriaceae.

CONCLUSIONS

Ceftolozane/tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than currently available cephalosporins and piperacillin/tazobactam when tested against Enterobacteriaceae.

Authors+Show Affiliations

JMI Laboratories, North Liberty, IA 52317, USA helio-sader@jmilabs.com.JMI Laboratories, North Liberty, IA 52317, USA.JMI Laboratories, North Liberty, IA 52317, USA.JMI Laboratories, North Liberty, IA 52317, USA.JMI Laboratories, North Liberty, IA 52317, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24917579

Citation

Sader, Helio S., et al. "Antimicrobial Activity of Ceftolozane/tazobactam Tested Against Pseudomonas Aeruginosa and Enterobacteriaceae With Various Resistance Patterns Isolated in European Hospitals (2011-12)." The Journal of Antimicrobial Chemotherapy, vol. 69, no. 10, 2014, pp. 2713-22.
Sader HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother. 2014;69(10):2713-22.
Sader, H. S., Farrell, D. J., Castanheira, M., Flamm, R. K., & Jones, R. N. (2014). Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). The Journal of Antimicrobial Chemotherapy, 69(10), 2713-22. https://doi.org/10.1093/jac/dku184
Sader HS, et al. Antimicrobial Activity of Ceftolozane/tazobactam Tested Against Pseudomonas Aeruginosa and Enterobacteriaceae With Various Resistance Patterns Isolated in European Hospitals (2011-12). J Antimicrob Chemother. 2014;69(10):2713-22. PubMed PMID: 24917579.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). AU - Sader,Helio S, AU - Farrell,David J, AU - Castanheira,Mariana, AU - Flamm,Robert K, AU - Jones,Ronald N, Y1 - 2014/06/10/ PY - 2014/6/12/entrez PY - 2014/6/12/pubmed PY - 2015/5/29/medline KW - ESBLs KW - XDR KW - cephalosporins KW - multidrug resistant KW - β-lactamase inhibitors SP - 2713 EP - 22 JF - The Journal of antimicrobial chemotherapy JO - J Antimicrob Chemother VL - 69 IS - 10 N2 - OBJECTIVES: To evaluate the in vitro activity of ceftolozane/tazobactam and comparator agents tested against contemporary Gram-negative bacteria. Ceftolozane/tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. METHODS: A total of 10 532 Gram-negative organisms (2191 Pseudomonas aeruginosa and 8341 Enterobacteriaceae) were consecutively collected from 31 medical centres located in 13 European countries plus Turkey and Israel. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A9 document and the results interpreted according to EUCAST as well as CLSI breakpoint criteria. Selected ceftazidime- and/or meropenem-resistant P. aeruginosa isolates were screened for the presence of β-lactamase genes by PCR. RESULTS: P. aeruginosa exhibited high rates of multidrug-resistant (31.9%) and extensively drug-resistant (24.6%) isolates and 11.6% of isolates were susceptible only to colistin. When tested against P. aeruginosa, ceftolozane/tazobactam (MIC(50), 1 mg/L) was generally 4-fold more active than ceftazidime (MIC(50), 4 mg/L) and inhibited >90% of isolates with an MIC of ≤8 mg/L in nine countries. In contrast, the highest susceptibility rates observed for ceftazidime and meropenem, respectively, were 86.0%/86.0% (UK) and 85.2%/86.1% (Ireland) (67.2%/67.1% overall). Ceftolozane/tazobactam (MIC(50/90), 0.25/2 mg/L; 93.7% and 95.2% inhibited at ≤4 and ≤8 mg/L, respectively), meropenem [MIC(50/90), ≤0.06/≤0.06 mg/L; 98.0% susceptible (EUCAST)] and tigecycline [MIC(50/90), 0.12/1 mg/L; 94.1% susceptible (EUCAST)] were the most active compounds tested against Enterobacteriaceae. CONCLUSIONS: Ceftolozane/tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than currently available cephalosporins and piperacillin/tazobactam when tested against Enterobacteriaceae. SN - 1460-2091 UR - https://www.unboundmedicine.com/medline/citation/24917579/Antimicrobial_activity_of_ceftolozane/tazobactam_tested_against_Pseudomonas_aeruginosa_and_Enterobacteriaceae_with_various_resistance_patterns_isolated_in_European_hospitals__2011_12__ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dku184 DB - PRIME DP - Unbound Medicine ER -